348 Studies Now Enrolling
Menu
Search
Displaying 1 - 68 of 68
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
This trial is testing an experimental treatment for HIV that is called CAB + RPV LA (long-acting cabotegravir and rilpivirine). CAB + RPV LA is a combination of drugs that is used to treat HIV (called antiretroviral therapy ART). It is currently approved in the US for the treatment of people…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
The HIV Vaccine Trials Network (HVTN), Division of AIDS (DAIDS), and Columbia University Irving Medical Center (CUIMC) are conducting a trial to learn about the safety and effectiveness of a new experimental HIV vaccine. The goal is to understand if the study products are safe to use in people…
Condition: Transplant / Liver Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Currently Recruiting
****The WiseApp in Spanish Study is looking for Spanish-speaking People Living with HIV Residing in the NYC Area**** Are you living with HIV? Are you 18 years or older? Are you a Spanish speaker? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
We are looking for individuals 18 to 60 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
The HIV Vaccine Trials Network (HVTN) and Columbia University Irving Medical Center (CUIMC) are conducting a study to learn about the safety and effectiveness of an experimental HIV vaccine. The study vaccine is a protein vaccine called N332-GT5 gp140. It includes a manmade protein that looks…
Condition: Infectious Disease / HIV
Investigator: Yael Hirsch-Moverman, PhD
Status: Currently Recruiting
HPTN 102/ PURPOSE 3 is a clinical study being done with cisgender women in the US to see whether an investigational twice-a-year (every 6 months) injection medicine can help reduce the risk of getting HIV from sex. The safety and efficacy of the medicine, which is called lenacapavir (LEN), is being studied for the prevention…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an…
Condition: Healthy Volunteers
Investigator: Ellen Morrison, MD, MPH
Status: Currently Recruiting
Come and talk with us about HIV prevention! HPTN 113-01/DUO is a series of 3 focus group discussions with young Latino/e/x cisgender men and gender nonbinary persons assigned male at birth (AMAB), who have sex with men. The focus groups will be conducted in English or Spanish, include 5-10 people, and be audio-recorded.…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
The HIV Vaccine Trials Network, Division of AIDS, and Columbia University Irving Medical Center are conducting a trial to learn about the safety and effectiveness of two new experimental HIV vaccines. This is a first-in-human phase 1 clinical trial where we will be testing 2 study vaccines,…
Condition: Healthy Volunteers
Investigator: Ellen Morrison, MD, MPH
Status: Currently Recruiting
PrEP (Pre-Exposure Prophylaxis) is medication that is taken to prevent HIV if a person is exposed to HIV. Research is ongoing to develop PrEP medications that may be both convenient and effective. This study is important because people who inject drugs face multiple overlapping individual, social…
Condition: Healthy Volunteers
Investigator: Ellen Morrison, MD, MPH
Status: Currently Recruiting
PrEP (Pre-Exposure Prophylaxis) is medication that is taken to prevent HIV if a person is exposed to HIV. Research is ongoing to identify PrEP medications that are both convenient and effective. This study is important because women in many areas of New York City have high rates of…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
Do you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding …
Condition: Infectious Disease
Investigator: Yael Hirsch-Moverman, PhD
Status: Currently Recruiting
ICAP/Harlem Prevention Center has been working to develop medications and strategies to help prevent HIV and other STIs since 2009. We are always looking for volunteers to participate in this research. Currently, we are looking for sexually-active individuals 18 years or older who are interested in learning more about our…
Condition: Infectious Disease / HIV
Investigator: Andrea Norcini Pala, PhD
Status: Closed
We are doing this research study to learn more about the lived experiences of discrimination and oppression based on race, sexual orientation, and HIV-status among Black men who have sex with men and live with HIV. We are interested in understanding how these experiences influence antiretroviral…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
HVTN 108 is an HIV vaccine study for 18-50 year old and HIV-negative people. We would like the test vaccine to teach your immune system to defend against HIV in a manner that is safe and well-tolerated. We will ask that all participants prevent…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
We are looking for individuals 18 to 60 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment (ART) is unable to reach. IL-15 superagonist (N-803) appears to reactivate HIV that is asleep and is also thought to increase the body's natural immune response to…
Condition: Infectious Disease / HIV
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
The HIV Vaccine Trials Network, Division of AIDS, and Columbia University Irving Medical Center are conducting a trial to learn about the safety and effectiveness of 3 experimental HIV vaccines. This is a first-in-human phase 1 clinical trial of experimental HIV…
Condition: Healthy Volunteers
Investigator: Julie Franks, PhD
Status: Closed
Almost 40,000 people get HIV in the U.S. each year and almost all infections occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year; however, we need other HIV prevention tools, including an effective HIV…
Condition: Transplant / Liver Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Closed
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications. This study will evaluate if receiving a liver transplant from an…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Did you know that people living with HIV are 50-100% more likely to develop heart disease (including heart attack and stroke) than people without HIV? And did you know that women with HIV are 3 times more likely to have a heart attack than women without…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
We are testing two antibodies directed against HIV virus. The human body uses antibodies as one way to help fight infection.The antibodies are called VRC01LS and VRC07-523LS and they are given by IV infusion. Each participant will receive one dose by infusion. The main purpose of this study is to see if these two antibodies…
Condition: Kidney Disease
Investigator: Marcus Pereira, MD, MPH
Status: Closed
This research is being done to learn whether organ transplantation from HIV-positive deceased donors is as safe and effective in HIV-positive recipients as transplants from HIV-negative deceased donors. People with end-stage organ disease and…
Condition: Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Closed
In this research study, we want to find out how well patients that receive a kidney from an HIV-positive (HIV+) donor do over 10 years compared to patients who receive a kidney from an HIV-negative (HIV-) donor. This research study is…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
This research study is being conducted to see if HIV antiretroviral medicines that you are taking continue to work well in transgender women and other individuals identifying as female or transfeminine, but with male sex assigned at birth (referred to as transgender) when taken with feminizing hormone therapy (FHT), also known…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
The purpose of the study is to test an experimental HIV vaccine. The study vaccine is made from two parts: a man-made piece of protein that looks like a protein found on the outside of HIV and an adjuvant. An adjuvant is a substance that helps the immune system respond better. The study will see…
Condition: Infectious Disease / HIV
Investigator: Jessica Justman, MD
Status: Closed
Pre-exposure prophylaxis, or PrEP, is the term used for medications that reduce the risk of getting HIV. There are approved medications that can be taken daily to prevent HIV infection. We are studying a PrEP medication that is a pill that can be taken once a month. It is being compared to an…
Condition: Infectious Disease / HIV
Investigator: Jessica Justman, MD
Status: Closed
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self-testing and PrEP adherence among cisgender and transgender women over a twelve-month period. We will help you to download the app on your phone and provide you with HIV self-test kits and PrEP (…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
****CHAMPS Study for People Living with HIV Residing in NYC Area**** Are you living with HIV? Are you 18 years or older? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University to learn more about how a phone app and…
Condition: Infectious Disease / HIV
Investigator: Julie Franks, PhD
Status: Closed
We are conducting a study to see if offering pre-exposure prophylaxis (PrEP) together with another health service that many transgender women use or would like to use, gender-affirming hormone therapy (GAHT), improves HIV-related outcomes, as compared to offering PrEP and referring study participants to get GAHT at area health…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
For People Living With HIV (PLWH) with HIV-Associated Non-AIDS (HANA) conditions such as cardiovascular disease or diabetes, the situation is complex given the added burden of coping with a secondary chronic illness and potential effects on treatment. How sex/gender differences in…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody.…
Condition: Infectious Disease / HIV
Investigator: Alex Carballo-Dieguez, MD
Status: Closed
This study will help scientists to understand the best ways to recruit and engage a wide variety of people (HIV-positive and HIV-negative) in HIV-related studies, using online recruitment methods. In this study you will be asked about topics including your…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
Are you living with HIV? Are you 18 years or older? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University to learn more about how a phone app and sessions with a community health worker can help people living with HIV…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
Interested in quitting smoking? Help researchers at Columbia University School of Nursing test an intervention to help people living with HIV quit smoking cigarettes! To be eligible you must be 18 years or older, be a person living with HIV, be a current smoker, be interested in quitting smoking…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
This study is looking at hepatitis B virus (HBV) vaccination in adults 18 to 70 years of age living with HIV around the world. Hepatitis B is a serious viral infection that affects the liver and is transmitted through blood and body fluids. A vaccine (a shot of medicine given through a needle) can prevent HBV, but there is no…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
The Wellness Study is a 6-month study looking at how a phone app, a fitness tracker, and a pill dispenser can help people living with HIV monitor and improve their health by tracking their fitness and helping them remember to take their medication. You may receive up to $200.00 for your participation.
Condition: Infectious Disease / HIV
Investigator: Sunil Wadhwa, DDS, PhD
Status: Closed
The study is looking for postmenopausal women between the ages of 35-70 years that have moderate periodontitis for a 1 year-long study which provides free dental cleaning. There are a total of 5 study visits, each one about 2 hours long, and each study visit provides you with $50, for a total of $250.
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
The mLab study at Columbia University is looking for cisgender men or trans women who are 18-29 years old and have sex with guys. Eligible individuals can earn up to $170 by participating in the online study and completing 3 surveys over the course of 1 year. Contact us if you are interested! Text/Call: 347-743-0104
Condition: Healthy Volunteers
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
The mLab study at Columbia University is looking for young cisgender men or trans women who are 18-29 years old and have sex with guys. Eligible individuals can earn up to $170 by participating in this LGBTQ+ health study and completing 3 online surveys over the course of 1 year. See if you're eligible to participate! Questions? Text us: 347-743-0104
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective …
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
We are working on a new HIV vaccine study that builds on past success and other ongoing studies. This new study is called HVTN 120 and is testing a vaccine for HIV prevention. The Thai Trial has been the only study where the vaccines were partially protective in preventing…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
We are looking for healthy, HIV-negative individuals 18 to 50 years old who are interested in our studies that test antibodies for HIV prevention. Antibodies are one of the natural ways that our bodies fight or prevent infection. We are testing an antibody called VRC07-523LS against…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
We are doing a research study to find out if Long-Acting Injectable anti-HIV medications will be more successful than standard pills for people who have a hard time taking their HIV pills. If you are over the age of 18 years old, have been prescribed HIV medications…
Condition: Healthy Volunteers
Investigator: Julie Franks, PhD
Status: Closed
We are conducting a study to see if offering pre-exposure prophylaxis (PrEP) together with another health service that many transgender women use or would like to use, gender-affirming hormone therapy (GAHT), improves HIV-related outcomes, as compared to offering PrEP and referring study participants to get GAHT at area health…
Condition: Healthy Volunteers
Investigator: Alex Carballo-Dieguez, MD
Status: Closed
This study will help scientists to understand the best ways to recruit and engage a wide variety of people (HIV-positive and HIV-negative) in HIV-related studies, using online recruitment methods. In this study you will be asked about topics including your…
Condition: Addiction / Alcohol
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if it doesn't make people feel uncomfortable and to find out what may be the best dose if its given by IV infusion or sub-cutaneous injection. You cannot get HIV from the Bispecific Antibody.…
Condition: Liver Disease / Hepatitis
Investigator: Jennifer Elliott, PhD
Status: Closed
NOTE: YOU MUST HAVE HIV AND HAVE EVER HAD HEPATITIS C TO BE ELIGIBLE FOR THIS STUDY!! ............... For individuals who have both HIV and Hepatitis C virus (HCV), heavy drinking poses serious risks to their health. We do not yet know which interventions are effective at helping individuals with…
Condition: Healthy Volunteers
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
Antibodies are one of the natural ways that our bodies fight or prevent infection. Were testing an antibody to find out if its safe, if they don't make people feel uncomfortable, how these study antibodies move throughout the body, and to measure antiviral activity. You cannot get HIV from the study antibody. Firstly, request…
Condition: Healthy Volunteers
Investigator: Cassia Wells, MD
Status: Closed
Antibodies are one of the natural ways that our bodies fight or prevent infection. We're testing an antibody to find out if it's safe, if they don't make people feel uncomfortable, how these study antibodies move throughout the body, and to measure antiviral activity. You cannot get HIV from the study antibody. First, request…
Condition: Transplant
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
Weight gain after starting antiretroviral therapy (ART) is common, but recent studies have found that some people living with HIV (PLWH) who are taking an integrase strand transfer inhibitor (INSTI) combined with tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir alafenamide/lamivudine (TAF/3TC) may gain more weight…
Condition: Infectious Disease / HIV
Investigator: Michael Yin, MD
Status: Closed
The study is exploring the impact of gender, age, HIV infection, and menopausal status on dental health. The study is open to men and women, ages 35-70.
A Study for Patients with Advanced Melanoma, Solid Tumors or Lymphoma Using Study Drug Pembrolizumab
Condition: Pediatrics / Cancer
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
The purpose of this study is to determine if a study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed, or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory…
Condition: Healthy Volunteers
Investigator: Stephen Arpadi, MD, MS
Status: Closed
We are seeking healthy volunteers (HIV-negative) for a study seeing if HIV is associated with faster biological aging among older African American adults, whether faster biological age is related to health conditions that typically occur in older people and whether these conditions might be due…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Condition: Healthy Volunteers
Investigator: Sharon Mannheimer, MD
Status: Closed
We are looking for adult volunteers to help us see if the FDA-approved Bexsero meningitis B vaccine can prevent people from getting gonorrhea infections. There are over 580,000 cases of gonorrhea diagnosed annually in the United States. Gonorrhea infections can significantly affect short and long-term reproductive health and contribute to increasing…
Condition: Infectious Disease
Investigator: Sharon Mannheimer, MD
Status: Closed
We are looking for adult volunteers to help us see if the FDA-approved Bexsero meningitis B vaccine can prevent people from getting gonorrhea infections. There are over 580,000 cases of gonorrhea diagnosed annually in the United States. Gonorrhea infections can significantly affect short and long-term reproductive health and contribute to increasing…
Condition: Healthy Volunteers
Investigator: Michael Yin, MD
Status: Closed
The study is exploring the impact of gender, age, HIV infection, and menopausal status on dental health. The study is open to men and women, ages 35-70.
Condition: COVID-19 (Coronavirus)
Investigator: Magdalena Sobieszczyk, MD
Status: Closed
The HIV Vaccine Trials Network (HVTN) and Columbia University Irving Medical Center are doing a study to learn more about SARS-CoV-2 infection and the COVID-19 disease that it can cause. The purpose of this study is to learn more about infection with and recovery from the virus called SARS-CoV-2. Some people know this virus by…
Condition: COVID-19 (Coronavirus)
Investigator: Jon Giles, MD
Status: Closed
If you currently live in the same household as someone who has tested positive for novel coronavirus (COVID-19), you might be eligible to participate in a trial that will test if a medicine used to prevent malaria, hydroxychloroquine, might reduce the risk of your developing COVID-19 symptoms. COVID-19 is a massive threat to public health worldwide. Post-…
Condition: Healthy Volunteers
Investigator: Rebecca Schnall, PhD, RN
Status: Closed
Take the Online Men's Health Survey (OMHS) today! Human Immunodeficiency Virus (HIV) and syphilis disproportionately affect men who have sex with men (MSM); however, this phenomenon is not well understood and is understudied in the United States. The OMHS study is being performed to help improve STI prevention and treatment…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE